Psoriasis and Fatty Liver Disease: Understanding the MASLD Link
Moderate to severe psoriasis is linked to an increased risk for metabolic dysfunction–associated steatotic liver disease, a condition characterized by fat accumulation in the liver that can progress to severe inflammation and fibrosis over time. Patients managing chronic inflammatory skin conditions face a compounded risk profile driven by shared systemic immune pathways and underlying metabolic abnormalities.
Psoriasis patients face up to four times the risk of developing metabolic dysfunction–associated steatotic liver disease compared to individuals without the skin condition, according to comparative clinical reviews.
Systemic inflammation driven by cytokines such as TNF-alpha and IL-17 interferes with normal lipid metabolism in the liver, contributing directly to cellular fat accumulation.
Routine clinical monitoring, lifestyle modifications targeting weight loss, and periodic hepatic screening via blood tests or imaging scans are essential for high-risk patients.
Understanding the Pathogenesis Connecting Psoriasis and Hepatic Lipid Accumulation
The intersection between chronic skin inflammation and hepatic complications involves complex biological mechanisms rather than a straightforward causal pathway. According to Meena B. Bansal, MD, a professor of medicine and director of the MASLD/MASH Center of Excellence at the Icahn School of Medicine at Mount Sinai in New York City, ongoing inflammatory signals from cytokines such as TNF-alpha and IL-17 interfere with how the liver handles fat, making hepatic lipid buildup much more likely. Dr. Bansal notes that metabolic syndrome components, including excess body weight and elevated blood sugar, independently raise hepatic risks, exposing patients to a double hit of shared inflammatory biology and metabolic dysfunction.
Clinical data underscore this elevated risk. A research review estimates that 34 percent of people with psoriasis and 46 percent of people with psoriatic arthritis experience metabolic syndrome. Regarding hepatic outcomes specifically, a separate review indicates that individuals with moderate to severe psoriasis are about four times as likely to develop metabolic dysfunction–associated steatotic liver disease (MASLD)—formerly known as nonalcoholic fatty liver disease—as those without the condition. Furthermore, a study utilizing magnetic resonance imaging found that 44 percent of participants with psoriasis or psoriatic arthritis exhibited MASLD, compared with 25 percent in a matched control group. According to Dr. Bansal, disease severity directly correlates with risk magnitude due to heightened systemic inflammatory activity.
Clinical Triage and Diagnostic Strategies for Lean and Systemic Phenotypes
Hepatic fat accumulation can develop even in patients who maintain a normal body weight. Joseph Lim, MD, a professor of medicine and director of clinical hepatology at the Yale School of Medicine in New Haven, Connecticut, explains that this phenotype, known as lean MASLD, occurs more frequently in patients with psoriasis who also present with diabetes. Because early-stage MASLD typically presents without noticeable symptoms, clinical suspicion and proactive screening are paramount. Diagnostic protocols often incorporate blood panels, specialized imaging scans, or, in select instances, liver biopsies to evaluate tissue architecture.
Early detection allows clinicians to map disease progression across established histological stages, moving from simple steatosis to metabolic dysfunction–associated steatohepatitis (MASH), fibrosis, and potentially cirrhosis.
Intervention Protocols and Therapeutic Management
Mitigating hepatic risk requires targeted lifestyle adjustments and medical management of comorbid conditions. Dr. Bansal recommends structured interventions including weight loss, dietary modifications that limit refined carbohydrates, increased physical activity combining aerobic and resistance training, strict limitations on alcohol consumption, and rigorous control of blood pressure, blood glucose, and lipid profiles. Achieving a 5 percent reduction in body weight can meaningfully decrease hepatic fat, while a 7 percent reduction can improve active inflammation. Additionally, reducing alcohol intake prevents compounding stress on an already vulnerable liver.
Pharmacological options are also evolving. According to Dr. Lim, biologic therapies utilized to manage primary dermatological symptoms appear neutral regarding liver fat but demonstrate meaningful benefits in reducing hepatic inflammation and biomarkers of fibrosis. For advanced disease states, interventions include U.S. Food and Drug Administration (FDA)-approved medications like resmetirom (Rezdiffra) for MASH with fibrosis stages 2 and 3, GLP-1 agonists, and bariatric surgery for eligible candidates with obesity and advanced liver disease.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.